CGTX — Cognition Therapeutics Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-Cognition Therapeutics, Pinterest, Minerva Neurosciences
Cognition Therapeutics up on positive data from Alzheimer’s drug study
Brief: Cognition Therapeutics Announces Positive Topline Results For CT1812 Phase 2 Sequel Study
Brief: Cognition Therapeutics Reports First Quarter 2023 Financial Results And Provides Business Update
Brief: Cognition Therapeutics Appoints John Doyle To Role Of CFO
Brief: Cognition Therapeutics Presents Proteomic Biomarker Data Of CT1812
Cognition Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Cognition Therapeutics Reports Year End 2022 Financial Results And Provides Business Update
Cognition Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Jack Henry, Coty, Netflix
U.S. STOCKS ON THE MOVE-Boeing, Alcoa, Canadian Pacific
U.S. STOCKS ON THE MOVE-Boxed, Roivant Sciences, U.S. banks
Cognition Therapeutics rises on FDA nod to begin mid-stage trials for eye drug
Brief: Cognition Therapeutics Announces Development Plans For Oral CT1812 In Geographic Atrophy Secondary to Dry AMD
U.S. STOCKS ON THE MOVE-Travel and leisure cos, Cognition Therapeutics, Natural gas
Cognition Therapeutics rises as U.S. FDA greenlights Alzheimer's drug study
Brief: Cognition Therapeutics Completes Enrollment Of CT1812 Phase 2 SEQUEL Study For Mild-To-Moderate Alzheimer’S Disease
Brief: Cognition Therapeutics Enters Into Controlled Equity Offering Sales Agreement
Brief: Cognition Therapeutics Files For Mixed Shelf Of Up To $200 Million- SEC Filing